Disparities in access to hematopoietic cell transplant persist at a transplant center.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
08
01
2024
accepted:
03
06
2024
revised:
30
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
Disparities in access to hematopoietic cell transplant (HCT) are well established. Prior studies have identified barriers, such as referral and travel to an HCT center, that occur before consultation. Whether differences in access persist after evaluation at an HCT center remains unknown. The psychosocial assessment for transplant eligibility may impede access to transplant after evaluation. We performed a single-center retrospective review of 1102 patients who underwent HCT consultation. We examined the association between race/ethnicity (defined as Hispanic, non-Hispanic Black, non-Hispanic White, and Other) and socioeconomic status (defined by zip code median household income quartiles and insurance type) with receipt of HCT and Psychosocial Assessment of Candidates for Transplantation (PACT) scores. Race/ethnicity was associated with receipt of HCT (p = 0.02) with non-Hispanic Whites comprising a higher percentage of HCT recipients than non-recipients. Those living in higher income quartiles and non-publicly insured were more likely to receive HCT (p = 0.02 and p < 0.001, respectively). PACT scores were strongly associated with income quartiles (p < 0.001) but not race/ethnicity or insurance type. Race/ethnicity and socioeconomic status impact receipt of HCT among patients evaluated at an HCT center. Further investigation as to whether the psychosocial eligibility evaluation limits access to HCT in vulnerable populations is warranted.
Identifiants
pubmed: 38871963
doi: 10.1038/s41409-024-02327-x
pii: 10.1038/s41409-024-02327-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2010;16:1070–5. https://doi.org/10.1016/j.bbmt.2009.12.529 .
doi: 10.1016/j.bbmt.2009.12.529
pubmed: 20036337
Hong S, Majhail NS. Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics. Hematology. 2021;2021:275–80. https://doi.org/10.1182/hematology.2021000259 .
doi: 10.1182/hematology.2021000259
pubmed: 34889386
pmcid: 8791157
Hamilton BK, Rybicki L, Sekeres M, Kalaycio M, Hanna R, Sobecks R, et al. Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites. Bone Marrow Transplant. 2015;50:834–9. https://doi.org/10.1038/bmt.2015.44 .
doi: 10.1038/bmt.2015.44
pubmed: 25798671
Hong S, Rybicki LA, Corrigan D, Schold JD, Majhail NS. Community risk score for evaluating health care disparities in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24:877–9. https://doi.org/10.1016/j.bbmt.2017.12.800 .
doi: 10.1016/j.bbmt.2017.12.800
pubmed: 29292058
Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116:3469–76. https://doi.org/10.1002/cncr.25297 .
doi: 10.1002/cncr.25297
pubmed: 20564154
Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017;123:1590–6. https://doi.org/10.1002/cncr.30526 .
doi: 10.1002/cncr.30526
pubmed: 28085188
Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3:2986–94. https://doi.org/10.1182/bloodadvances.2019000308 .
doi: 10.1182/bloodadvances.2019000308
pubmed: 31648322
pmcid: 6849958
Winestone LE, Li Q, Muffly LS, Getz KD, Alvarez E, Wun T, et al. Disparities in the use of allogeneic hematopoietic stem cell transplant among children, adolescents, and young adults with acute leukemia in California. Blood. 2020;136:4–5. https://doi.org/10.1182/blood-2020-142240 .
doi: 10.1182/blood-2020-142240
Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:63–7. https://doi.org/10.1038/bmt.2012.95 .
doi: 10.1038/bmt.2012.95
pubmed: 22705801
Mitchell JM, Conklin EA. Factors affecting receipt of expensive cancer treatments and mortality: evidence from stem cell transplantation for leukemia and lymphoma. Health Serv Res. 2015;50:197–216. https://doi.org/10.1111/1475-6773.12208 .
doi: 10.1111/1475-6773.12208
pubmed: 25047947
Kanate AS, Perales MA, Hamadani M. Eligibility criteria for patients undergoing allogeneic hematopoietic cell transplantation. J Natl Compr Cancer Netw. 2020;18:635–43. https://doi.org/10.6004/jnccn.2020.7559 .
doi: 10.6004/jnccn.2020.7559
Carreras E, Rambaldi A. Evaluation and counseling of candidates. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Cham: Springer; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553925/ .
McQuellon RP, Duckworth KE. Psychosocial issues in hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin, JH, Appelbaum FR editors. Thomas’ hematopoietic cell transplantation. Wiley; 2015. pp. 384–93. https://doi.org/10.1002/9781118416426.ch32 .
Snyder DS. Ethical issues in hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin, JH, Appelbaum FR editors. Thomas’ hematopoietic cell transplantation. Wiley; 2015. pp. 374–85. https://doi.org/10.1002/9781118416426.ch31 .
Kuntz K, Weinland SR, Butt Z. Psychosocial challenges in solid organ transplantation. J Clin Psychol Med Settings. 2015;22:122–35. https://doi.org/10.1007/s10880-015-9435-6 .
doi: 10.1007/s10880-015-9435-6
pubmed: 26370201
Olbrisch ME, Levenson JL, Hamer RM. The PACT: a rating scale for the study of clinical decision-making in psychosocial screening of organ transplant candidates. Clin Transplant. 1989;3:164–9.
Hitschfeld MJ, Schneekloth TD, Kennedy CC, Rummans TA, Niazi SK, Vasquez AR, et al. The psychosocial assessment of candidates for transplantation: a cohort study of its association with survival among lung transplant recipients. Psychosomatics. 2016;57:489–97. https://doi.org/10.1016/j.psym.2016.05.003 .
doi: 10.1016/j.psym.2016.05.003
pubmed: 27494985
Hong S, Rybicki L, Corrigan D, Dabney J, Hamilton BK, Kalaycio M, et al. Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients. Bone Marrow Transplant. 2019;54:1443–52. https://doi.org/10.1038/s41409-019-0455-y .
doi: 10.1038/s41409-019-0455-y
pubmed: 30696998
pmcid: 6663643
Harashima S, Yoneda R, Horie T, Fujioka Y, Nakamura F, Kurokawa M, et al. Psychosocial Assessment of Candidates for Transplantation scale (PACT) and survival after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54:1013–21. https://doi.org/10.1038/s41409-018-0371-6 .
doi: 10.1038/s41409-018-0371-6
pubmed: 30353064
Solh MM, Speckhart D, Solomon SR, Bashey A, Morris LE, Zhang X, et al. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2020;4:4812–21. https://doi.org/10.1182/bloodadvances.2020002204 .
doi: 10.1182/bloodadvances.2020002204
pubmed: 33022065
pmcid: 7556142
Foster LW, McLellan L, Rybicki L, Dabney J, Visnosky M, Bolwell B. Utility of the psychosocial assessment of candidates for transplantation (PACT) scale in allogeneic BMT. Bone Marrow Transplant. 2009;44:375–80. https://doi.org/10.1038/bmt.2009.37 .
doi: 10.1038/bmt.2009.37
pubmed: 19290003
Broers S, Hengeveld MW, Kaptein AA, Le Cessie S, van de Loo F, de Vries T. Are pretransplant psychological variables related to survival after bone marrow transplantation? A prospective study of 123 consecutive patients. J Psychosom Res. 1998;45:341–51. https://doi.org/10.1016/s0022-3999(98)00003-8 .
doi: 10.1016/s0022-3999(98)00003-8
pubmed: 9794280
Cooper RS, Nadkarni GN, Ogedegbe G. Race, ancestry, and reporting in medical journals. JAMA. 2018;320:1531–2. https://doi.org/10.1001/jama.2018.10960 .
doi: 10.1001/jama.2018.10960
pubmed: 30264132
Flanagin A, Frey T, Christiansen SL. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326:621–7. https://doi.org/10.1001/jama.2021.13304 .
doi: 10.1001/jama.2021.13304
pubmed: 34402850
2018 Introduction to the NIS. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 2021. www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2018.jsp . Accessed 21 Nov 2023.
Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible - the neighborhood atlas. N Engl J Med. 2018;378:2456–8. https://doi.org/10.1056/NEJMp1802313 .
doi: 10.1056/NEJMp1802313
pubmed: 29949490
pmcid: 6051533
Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10:220–7. https://doi.org/10.1016/j.hemonc.2017.05.009 .
doi: 10.1016/j.hemonc.2017.05.009
pubmed: 28641097
pmcid: 5925745
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004 .
doi: 10.1182/blood-2005-05-2004
pubmed: 15994282
pmcid: 1895304
Foster LW, McLellan LJ, Rybicki LA, Dabney J, Welsh E, Bolwell BJ. Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals. Bone Marrow Transplant. 2006;37:223–8. https://doi.org/10.1038/sj.bmt.1705219 .
doi: 10.1038/sj.bmt.1705219
pubmed: 16273113
WHO. 3, Household crowding. In: Housing and health guidelines. Geneva: World Health Organization; 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535289/ .
Applebaum AJ, Bevans M, Son T, Evans K, Hernandez M, Giralt S, et al. A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions. Bone Marrow Transplant. 2016;51:1416–22. https://doi.org/10.1038/bmt.2016.164 .
doi: 10.1038/bmt.2016.164
pubmed: 27295270
pmcid: 5564416
Auletta JJ, Sandmaier BM, Jensen E, Majhail NS, Knutson J, Nemecek E, et al. The ASTCT-NMDP ACCESS initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem. Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther. 2022;28:802–9. https://doi.org/10.1016/j.jtct.2022.09.020 .
doi: 10.1016/j.jtct.2022.09.020
D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177–e182. https://doi.org/10.1016/j.bbmt.2020.04.013 .
doi: 10.1016/j.bbmt.2020.04.013
pubmed: 32438042
pmcid: 7404814